January 11, 2024 09:45 AM EST
News Briefing

Der­ma­van­t's PhI­II eczema da­ta; Ox­ford's Ni­pah vac­cine; In­ven­ti­va's €25M life­line

Max Gelman

Senior Editor

Reynald Castañeda

Deputy Editor

Der­ma­vant re­port­ed new Phase III da­ta for its atopic der­mati­tis cream Vta­ma on Thurs­day morn­ing, say­ing more than 80% of par­tic­i­pants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

An­oth­er Bris­tol My­ers ex­ec goes to Aca­dia; David South­well takes CEO job at ARCH-backed can­cer biotech

As a chal­leng­ing first half nears a close, bio­phar­ma un­cer­tain­ty per­sists

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times